| SUD- Group | SUD+ Group |  |  |  | ||
---|---|---|---|---|---|---|---|
 | N | % | N | % | OR | 95% CI | p |
Known vs. Unknown Genotype | Â | Â | Â | Â | Â | Â | Â |
   Not available | 42 | 12.0% | 52 | 11.2% | 1.08 | 0.70–1.67 | 0.718 |
   Available | 308 | 88.0% | 413 | 88.8% |  |  |  |
Genotypes 2 & 3 | Â | Â | Â | Â | Â | Â | Â |
Completed ≥ 22 Weeks of IFN |  |  |  |  |  |  |  |
   No | 29 | 26.9% | 56 | 32.0% | 0.78 | 0.46 – 1.33 | 0.359 |
   Yes | 79 | 73.1% | 119 | 68.0% |  |  |  |
End of Treatment Response (ETR) | Â | Â | Â | Â | Â | Â | Â |
   Not available | 8 | 7.4% | 9 | 5.1% | 1.38 | 0.51 – 3.74 | 0.528 |
   Available | 71 | 65.7% | 110 | 62.9% |  |  |  |
No Response | 14 | 13.0% | 15 | 8.6% | 1.56 | 0.70 – 3.46 | 0.276 |
Response | 57 | 52.8% | 95 | 54.3% | Â | Â | Â |
Sustained Viral Response (SVR) | Â | Â | Â | Â | Â | Â | Â |
   Not available | 4 | 3.7% | 8 | 4.6% | 0.79 | 0.23 – 2.73 | 0.705 |
   Available | 61 | 56.5% | 96 | 54.9% |  |  |  |
No Response | 15 | 13.9% | 24 | 13.7% | 0.98 | 0.47 – 2.06 | 0.954 |
Response | 46 | 42.6% | 72 | 41.1% | Â | Â | Â |
Genotypes 1 & 4 | Â | Â | Â | Â | Â | Â | Â |
Completed ≥ 46 Weeks of IFN |  |  |  |  |  |  |  |
   No | 121 | 60.5% | 143 | 60.1% | 1.02 | 0.69 – 1.49 | 0.929 |
   Yes | 79 | 39.5% | 95 | 39.9% |  |  |  |
End of Treatment Response (ETR) | Â | Â | Â | Â | Â | Â | Â |
   Not available | 9 | 8.3% | 19 | 10.9% | 0.51 | 0.22 – 1.21 | 0.124 |
   Available | 70 | 64.8% | 76 | 43.4% |  |  |  |
No Response | 21 | 19.4% | 17 | 9.7% | 1.49 | 0.71 – 3.13 | 0.294 |
Response | 49 | 45.4% | 59 | 33.7% | Â | Â | Â |
Sustained Viral Response (SVR) | Â | Â | Â | Â | Â | Â | Â |
   Not available | 3 | 2.8% | 4 | 2.3% | 1.01 | 0.22 – 4.69 | 0.991 |
   Available | 55 | 50.9% | 74 | 42.3% |  |  |  |
No Response | 23 | 21.3% | 21 | 12.0% | 1.81 | 0.87 – 3.79 | 0.111 |
Response | 32 | 29.6% | 53 | 30.3% | Â | Â | Â |